Galaxy Therapeutics secures CE mark for embolisation system
Galaxy will now initiate a phased commercial rollout of its saccular endovascular aneurysm lattice (SEAL) across select European markets.
Galaxy will now initiate a phased commercial rollout of its saccular endovascular aneurysm lattice (SEAL) across select European markets.
With regulatory conditions tightening around climate impact and environmental persistence of medical propellants, HFA-152a is a practical route to maintain clinical performance, patient outcomes and supply continuity of inhalers. However,...
The medical devices industry continues to be a hotbed of patent innovation. Activity is driven by increased need for homecare,...
UK government champions healthtech through new NHS access programme
Intuitive Surgical expands platforms despite market headwind
The increased importance of safety for wearable devices
What does the EU Data Act mean for businesses?